Field Trip Psychedelics is planning to go public via a "three-cornered" RTO.
Exploring the companies and themes that make up this emerging and exciting new sector
Osoyoos Announces Agreement to Acquire AI Pharmaceuticals Jamaica Limited
Osoyoos cannabis has acquired a psilocybin-focuse biopharma company based in Jamaica.
Mydecine Innovations Group Inc. Signs Partnership Agreement With Applied Pharmaceutical Innovation
Mydecine announces research agreement with a leading pharmacology research institution.
North Sur Resources and Mindset Pharma Announce Proposed Transaction to Accelerate Development of Medical Psychedelics Industry
An amalgamation of two private companies as psychedelics company Mindset Pharma Inc prepares to go public.
Red Light Holland Engages Former Health Minister, the Honourable, Tony P. Clement, as Senior Advisor to Advisory Board
Former Canada Health Minister joins Red Light Holland as Senior Advisor.
Mydecine Innovations Group Adds Former Pfizer, Novartis, Yale Drug Discovery Expert to Scientific Advisory Board
Mydecine's new Scientific Advisor will work directly with the CSO in drug development initiatives.
What Does Field Trip Psychedelics Offer Investors?
Field Trip Psychedelics has just announced a letter of intent to go public via RTO.
Champignon Brands Announces Regulatory Review, Cease Trade Order
Trading of Champignon Brands (SHRM) on the Canadian Securities Exchange has been temporarily halted due to the failure to file necessary disclosures with respect to recent acquisitions.
COMPASS Pathways Strengthens Leadership Team With Appointment of Trevor Mill as Chief Development Officer
Compass appoints a new Chief Development Officer as part of several new appointments to its management team.
Red Light Holland Announces The Closing of Second Tranche of Private Placement
With the closing of its second tranche, Red Light Holland has now raised $3,830,529 in its current private placement.
Canadians More Receptive To Use Of Psilocybin For The Terminally Ill: New Poll
Canadians are rapidly warming up to the idea of using psilocybin to reduce distress among the terminally ill.
ATAI launches IntroSpect Digital Therapeutics, Appoints veteran software engineer David Keene as CEO
ATAI is adding a digital therapeutics division to its R&D platform.